We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Test Specifically Detects Mobile Colistin Resistance in Isolates

By LabMedica International staff writers
Posted on 22 Feb 2017
Scientists have evaluated a commercially available LAMP-based assay for rapid detection of the plasmid-encoded mobile colistin resistance gene mcr-1 in Enterobacteriaceae isolates. More...
With further development and evaluation, it can likely also be used in hospitals and for livestock.

Scientists from the German Center for Infection Research (DZIF) and the Justus Liebig University (JLU) Giessen (also Giessen University) evaluated the test, which detects the mcr-1 within 20 minutes.

Colistin is used as a “last-resort antibiotic” for multidrug-resistant pathogens, especially in hospitals. However, some gut bacteria have become insensitive to colistin due to the mobile colistin resistance gene mcr-1. In early 2016, bacteria carrying mcr-1 were detected in Germany for the first time and there is growing concern that it may develop into a superbug against which even emergency antibiotics are no longer effective. Risk of further spread of this colisitin resistance is high because it takes place through plasmids, which are transferred between different types of bacteria relatively easily.

“Confirming the mobile mcr-1 resistance gene as rapidly as possible is important so as to prevent its further spread,” emphasized Linda Falgenhauer, DZIF scientist at Giessen University and a co-first-author of this study. She, with colleagues from Giessen University and from the research association RESET, tested a rapid genotypic resistance test for colistin that is already commercially available. “This is the only way with which mobile resistance can be differentiated from common resistance, because phenotypically they are the same,” said co-first-author Can Imirzalioglu, DZIF scientist at Giessen University.

For the evaluation of this test, AmplexBiosystems GmbH provided the testing kits free of charge. The scientists tested 104 bacterial isolates from animals, humans, and the environment: the results were compared to those from complete genome sequencing or PCR, and demonstrated 100% sensitivity and specificity. So the test could clearly differentiate between common colistin resistance and mobile resistance located on plasmids. However, applying the test directly to clinical samples has not yet been evaluated, it only been applied to bacterial cultures.

“The test results become available in only twenty minutes,” said co-author Judith Schmiedel, from the Giessen team, “With the conventional procedure, it takes several hours to get results. Additionally, the system is very uncomplicated, so it should be developed further for future use in hospitals as well as for livestock farming and food production.” With an “interdisciplinary collaboration, we are following the One Health approach which takes into account the systemic connections between humans, animals, the environment, and health in order to fight antibiotic resistance,” said Prof. Trinad Chakraborty, of JLU Giessen and coordinator of the DZIF partner-site Giessen-Marburg-Langen.

The study, by Imirzalioglu C et al, was published online ahead of print January 30, 2017, in the journal Antimicrobial Agents and Chemotherapy.


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.